145 related articles for article (PubMed ID: 35300932)
1. Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.
Gold LS; Hansen RN; Patrick DL; Tabah A; Heltshe SL; Flume PA; Goss CH; West NE; Sanders DB; VanDevanter DR; Kessler L
J Cyst Fibros; 2022 Jul; 21(4):594-599. PubMed ID: 35300932
[TBL] [Abstract][Full Text] [Related]
2. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.
Goss CH; Heltshe SL; West NE; Skalland M; Sanders DB; Jain R; Barto TL; Fogarty B; Marshall BC; VanDevanter DR; Flume PA;
Am J Respir Crit Care Med; 2021 Dec; 204(11):1295-1305. PubMed ID: 34469706
[No Abstract] [Full Text] [Related]
4. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
5. Duration of intravenous antibiotic therapy in people with cystic fibrosis.
Abbott L; Plummer A; Hoo ZH; Wildman M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD006682. PubMed ID: 31487382
[TBL] [Abstract][Full Text] [Related]
6. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
[TBL] [Abstract][Full Text] [Related]
7. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
[TBL] [Abstract][Full Text] [Related]
8. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.
Nash EF; Choyce J; Carrolan V; Justice E; Shaw KL; Sitch A; Mistry H; Whitehouse JL
Ther Adv Respir Dis; 2022; 16():17534666211070133. PubMed ID: 35274585
[TBL] [Abstract][Full Text] [Related]
10. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
[No Abstract] [Full Text] [Related]
11. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
[No Abstract] [Full Text] [Related]
12. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.
Waters V; Stanojevic S; Klingel M; Chiang J; Sonneveld N; Kukkar R; Tullis E; Ratjen F
J Cyst Fibros; 2015 Nov; 14(6):770-6. PubMed ID: 26265220
[TBL] [Abstract][Full Text] [Related]
13. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
14. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
Sanders DB; Zhao Q; Li Z; Farrell PM
Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
16. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.
Lo DK; Muhlebach MS; Smyth AR
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009650. PubMed ID: 30030966
[TBL] [Abstract][Full Text] [Related]
17. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007.
Briesacher BA; Quittner AL; Fouayzi H; Zhang J; Swensen A
Pediatr Pulmonol; 2011 Aug; 46(8):770-6. PubMed ID: 21465674
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
[TBL] [Abstract][Full Text] [Related]
19. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.
Heimeshoff M; Hollmeyer H; Schreyögg J; Tiemann O; Staab D
Pharmacoeconomics; 2012 Sep; 30(9):763-77. PubMed ID: 22690685
[TBL] [Abstract][Full Text] [Related]
20. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations.
VanDevanter DR; O'Riordan MA; Blumer JL; Konstan MW
Respir Res; 2010 Oct; 11(1):137. PubMed ID: 20925941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
